無料プレビュー

Vertex Pharmaceuticals Incorporated (VRTX) · NASDAQ Global Select

プロフィール

Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercializes transformative medicines for serious diseases with a focus on specialty markets. The company markets approved medicines for cystic fibrosis (five products), sickle cell disease and transfusion-dependent beta thalassemia (CASGEVY), and acute pain (JOURNAVX), and maintains a clinical pipeline spanning IgA nephropathy, APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, autosomal dominant polycystic kidney disease, and myotonic dystrophy type 1. Verte

主要指標

株価: $506.32 (+0.13%)
時価総額: 1,285億ドル
PER（今期予想）: 27.1
PBR: 6.3
配当利回り: —
52週レンジ: $402.58 – $560.25
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: S&P 500 0.19% · Nasdaq 100 0.52%

比較会社: MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.、ROIV Roivant Sciences Ltd.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-02 · 更新: 2026-10-08